Nelson H. Tsuno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nelson H. Tsuno has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Eiji Sunami
Department of Surgical Oncology, Japanese Red Cross Medical Center, Tokyo, Japan
5 shared publications - Joji Kitayama
Department of Surgical Oncology, Japan Institute for Health Security, Tokyo 162-8655, Japan
5 shared publications Koki Takahashi
Department of Transfusion Medicine The University of Tokyo Giessen Germany
4 shared publicationsM. Matsuhashi
Department of Transfusion Medicine The University of Tokyo Tokyo Japan
3 shared publicationsS. Santoso
Institute for Clinical Immunology and Transfusion Medicine Justus Liebig University Giessen Germany
3 shared publications- Toshiaki Watanabe
Center for Regenerative Medicine, National Center for Child Health and Development (NCCHD), Tokyo, Japan
3 shared publications
Latest Publications
- 1 January 2018
- Published by Japan Society of Transfusion Medicine and Cell Therapy in Japanese Journal of Transfusion and Cell Therapy
- Vol. 64 (1) , 28-34
THE PREVALENCE OF JK*A with c.130A SINGLE NUCLEOTIDE POLYMORPHISM IN THE JAPANESE BLOOD DONORS AND EXPRESSION ANALYSIS OF Jka AND Jk3 ANTIGENS ON THEIR RED BLOOD CELLS
- 1 January 2018
- Published by Japan Society of Transfusion Medicine and Cell Therapy in Japanese Journal of Transfusion and Cell Therapy
- Vol. 64 (1) , 28-34
THE PREVALENCE OF JK*A with c.130A SINGLE NUCLEOTIDE POLYMORPHISM IN THE JAPANESE BLOOD DONORS AND EXPRESSION ANALYSIS OF Jka AND Jk3 ANTIGENS ON THEIR RED BLOOD CELLS
- 1 March 2015
- Vol. 35 (3) , 1459-64
Phosphatidylserine-specific phospholipase A1 (PS-PLA1) expression in colorectal cancer correlates with tumor invasion and hematogenous metastasis.
The function of phosphatidylserine-specific phospholipase A1 (PS-PLA1), a phospholipase that acts specifically on phosphatidylserine and produces lysophosphatidylserine, a lysophospholipid mediator, has not been fully elucidated. We evaluated the role of PS-PLA1 in oncogenesis and metastasis of colorectal cancer (CRC). Specimens from 85 patients with CRC were immunostained with a monoclonal antibody against PS-PLA1. The correlation between PS-PLA1 expression and the clinicopathological variables was analyzed. Tumor depth and hematogenous metastasis independently positively correlated with PS-PLA1 expression. High PS-PLA1 expression was associated with shorter disease-free survival, although it was not an independent predictive factor. PS-PLA1 expression in CRC is associated with tumor invasion and metastasis.
- 1 March 2015
- Vol. 35 (3) , 1459-64
Phosphatidylserine-specific phospholipase A1 (PS-PLA1) expression in colorectal cancer correlates with tumor invasion and hematogenous metastasis.
The function of phosphatidylserine-specific phospholipase A1 (PS-PLA1), a phospholipase that acts specifically on phosphatidylserine and produces lysophosphatidylserine, a lysophospholipid mediator, has not been fully elucidated. We evaluated the role of PS-PLA1 in oncogenesis and metastasis of colorectal cancer (CRC). Specimens from 85 patients with CRC were immunostained with a monoclonal antibody against PS-PLA1. The correlation between PS-PLA1 expression and the clinicopathological variables was analyzed. Tumor depth and hematogenous metastasis independently positively correlated with PS-PLA1 expression. High PS-PLA1 expression was associated with shorter disease-free survival, although it was not an independent predictive factor. PS-PLA1 expression in CRC is associated with tumor invasion and metastasis.
- Open Access
- 1 January 2015
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 13 (1) , 7
Immunohistochemical detection of high-mobility group box 1 correlates with resistance of preoperative chemoradiotherapy for lower rectal cancer: a retrospective study
High-mobility group box 1 (HMGB1) is a nucleoprotein that is related to inflammation. It has been implicated in a variety of biologically important processes, including transcription, DNA repair, differentiation, development, and extracellular signaling. Recently, its important role in the process of tumor invasion, metastasis, and resistance to anti-cancer therapies has been demonstrated. In this study, we aimed to investigate the correlation of HMGB1 expression and resistance of rectal cancer patients to chemoradiotherapy (CRT) prior to curative operation. We retrospectively reviewed the data of 75 lower rectal cancer patients without complete pathological response who had received preoperative CRT and had undergone curative resection at the University of Tokyo Hospital between May 2003 and June 2010. HMGB1 expression in surgically resected specimens was evaluated using immunohistochemical detection and specimens were classified into high or low HMGB1 expression groups. Clinicopathologic features, degree of tumor reduction, regression of tumor grade, and patient survival were compared between the groups using non-paired Student’s t-tests and Kaplan-Meier analysis. A total of 52 (69.3%) patients had high HMGB1 expression, and 23 (30.7%) had low expression. HMGB1 expression was significantly correlated with histologic type (P = 0.02), lymphatic invasion (P = 0.02), and venous invasion (P = 0.05). Compared to patients with low HMGB1 expression, those with high expression had a poorer response to CRT, in terms of tumor reduction ratio (42.2 versus 28.9%, respectively; P <0.01) and post-CRT histological tumor regression grade (56.5 versus 30.8% grade 2; respectively; P = 0.03). However, no significant correlation was found between HMGB1 expression and recurrence-free and overall survival rates. HMGB1 expression may be one of the key factors regulating the response of rectal cancer to preoperative CRT in terms of tumor invasiveness and resistance to therapy.
- 1 January 2015
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 13 (1) , 7
Open AccessImmunohistochemical detection of high-mobility group box 1 correlates with resistance of preoperative chemoradiotherapy for lower rectal cancer: a retrospective study
High-mobility group box 1 (HMGB1) is a nucleoprotein that is related to inflammation. It has been implicated in a variety of biologically important processes, including transcription, DNA repair, differentiation, development, and extracellular signaling. Recently, its important role in the process of tumor invasion, metastasis, and resistance to anti-cancer therapies has been demonstrated. In this study, we aimed to investigate the correlation of HMGB1 expression and resistance of rectal cancer patients to chemoradiotherapy (CRT) prior to curative operation. We retrospectively reviewed the data of 75 lower rectal cancer patients without complete pathological response who had received preoperative CRT and had undergone curative resection at the University of Tokyo Hospital between May 2003 and June 2010. HMGB1 expression in surgically resected specimens was evaluated using immunohistochemical detection and specimens were classified into high or low HMGB1 expression groups. Clinicopathologic features, degree of tumor reduction, regression of tumor grade, and patient survival were compared between the groups using non-paired Student’s t-tests and Kaplan-Meier analysis. A total of 52 (69.3%) patients had high HMGB1 expression, and 23 (30.7%) had low expression. HMGB1 expression was significantly correlated with histologic type (P = 0.02), lymphatic invasion (P = 0.02), and venous invasion (P = 0.05). Compared to patients with low HMGB1 expression, those with high expression had a poorer response to CRT, in terms of tumor reduction ratio (42.2 versus 28.9%, respectively; P <0.01) and post-CRT histological tumor regression grade (56.5 versus 30.8% grade 2; respectively; P = 0.03). However, no significant correlation was found between HMGB1 expression and recurrence-free and overall survival rates. HMGB1 expression may be one of the key factors regulating the response of rectal cancer to preoperative CRT in terms of tumor invasiveness and resistance to therapy.
- 1 November 2014
- Published by Wiley in ISBT Science Series
- Vol. 9 (2) , 304-308
Report of the First Workshop of the ISBT International Platelet Immunobiology Working Party, Asia Regional
- 1 November 2014
- Published by Wiley in ISBT Science Series
- Vol. 9 (2) , 304-308
Report of the First Workshop of the ISBT International Platelet Immunobiology Working Party, Asia Regional
- 1 October 2014
- Vol. 34 (10) , 5465-72
Lysophosphatidylserine stimulates chemotactic migration of colorectal cancer cells through GPR34 and PI3K/Akt pathway.
Lysophosphatidylserine (lysoPS) is a type of lysophospholipid mediator, which is involved in allergic conditions and tumor progression. We investigated the physiological function of lysoPS on colorectal cancer (CRC) cell lines, as well as the involved receptor and signaling pathways. Expression of lysoPS receptors on six cell lines was examined by reverse transcription-polymerase chain reaction (RT-PCR). The physiological functions of lysoPS were investigated, and experiments using small interfering RNA (siRNA) or inhibitors of the signaling pathways were conducted. Among the three lysoPS receptors, GPR34 was highly expressed on all cell lines. LysoPS stimulated the chemotactic migratory ability. Wortmannin inhibited the migratory ability, as well as the GPR34 knock-down, strongly suggestive of the involvement of this receptor in the PI3K/Akt pathway. The involved receptor and pathways in the migratory ability in response to lysoPS was demonstrated, which opens premises for targeting as a new strategy for prevention and treatment of colorectal cancer.
- 1 October 2014
- Vol. 34 (10) , 5465-72
Lysophosphatidylserine stimulates chemotactic migration of colorectal cancer cells through GPR34 and PI3K/Akt pathway.
Lysophosphatidylserine (lysoPS) is a type of lysophospholipid mediator, which is involved in allergic conditions and tumor progression. We investigated the physiological function of lysoPS on colorectal cancer (CRC) cell lines, as well as the involved receptor and signaling pathways. Expression of lysoPS receptors on six cell lines was examined by reverse transcription-polymerase chain reaction (RT-PCR). The physiological functions of lysoPS were investigated, and experiments using small interfering RNA (siRNA) or inhibitors of the signaling pathways were conducted. Among the three lysoPS receptors, GPR34 was highly expressed on all cell lines. LysoPS stimulated the chemotactic migratory ability. Wortmannin inhibited the migratory ability, as well as the GPR34 knock-down, strongly suggestive of the involvement of this receptor in the PI3K/Akt pathway. The involved receptor and pathways in the migratory ability in response to lysoPS was demonstrated, which opens premises for targeting as a new strategy for prevention and treatment of colorectal cancer.
- 22 October 2013
- Published by Wiley in Transfusion
- Vol. 54 (4) , 1093-1099
The role of alloantibodies against human platelet antigen‐15 in multiply platelet transfused patients
Background: Several studies have documented the role of antibodies against human platelet (PLT) antigen (HPA)‐15 in alloimmune‐mediated thrombocytopenia including neonatal alloimmune thrombocytopenia, PLT transfusion refractoriness (PTR), and posttransfusion purpura in Caucasian persons. However, the relevance of anti‐HPA‐15 in PTR among the Japanese population is still unclear.Study Design and Methods: The sera of 305 multiply PLT transfused (MPT) patients, previously investigated for the presence of human leukocyte antigen (HLA) and HPA antibodies by mixed passive hemagglutination, were reexamined for the presence of HPA‐15 alloantibodies, using the monoclonal antibody–specific immobilization of PLT antigens (MAIPA) technique.Results: Among the 305 MPT samples, antibodies against HPA‐15 alloantigen was detected in seven (2.3%), two (0.66%) being anti‐HPA‐15a and five (1.64%) being anti‐HPA‐15b. Additionally, one case of CD109 panreactive antibody was found (0.33%). Among them, one aplastic anemia patient with blood group O developed multispecific anti‐HLA and anti‐HPA‐15b alloantibody after MPTs. However, transfusion with HLA‐matched PLTs of blood group AB did not result in adequate PLT count increment. Analysis of the possible influence of immune anti‐A and anti‐B by the MAIPA assay resulted negative, indicating that anti‐HPA‐15b is responsible for the refractory state in this patient.Conclusion: In this study, we found alloimmunization against HPA‐15a and ‐15b in Japanese populations and demonstrated the relevance of these antibodies in a patient with PTR.
- 22 October 2013
- Published by Wiley in Transfusion
- Vol. 54 (4) , 1093-1099
The role of alloantibodies against human platelet antigen‐15 in multiply platelet transfused patients
Background: Several studies have documented the role of antibodies against human platelet (PLT) antigen (HPA)‐15 in alloimmune‐mediated thrombocytopenia including neonatal alloimmune thrombocytopenia, PLT transfusion refractoriness (PTR), and posttransfusion purpura in Caucasian persons. However, the relevance of anti‐HPA‐15 in PTR among the Japanese population is still unclear.Study Design and Methods: The sera of 305 multiply PLT transfused (MPT) patients, previously investigated for the presence of human leukocyte antigen (HLA) and HPA antibodies by mixed passive hemagglutination, were reexamined for the presence of HPA‐15 alloantibodies, using the monoclonal antibody–specific immobilization of PLT antigens (MAIPA) technique.Results: Among the 305 MPT samples, antibodies against HPA‐15 alloantigen was detected in seven (2.3%), two (0.66%) being anti‐HPA‐15a and five (1.64%) being anti‐HPA‐15b. Additionally, one case of CD109 panreactive antibody was found (0.33%). Among them, one aplastic anemia patient with blood group O developed multispecific anti‐HLA and anti‐HPA‐15b alloantibody after MPTs. However, transfusion with HLA‐matched PLTs of blood group AB did not result in adequate PLT count increment. Analysis of the possible influence of immune anti‐A and anti‐B by the MAIPA assay resulted negative, indicating that anti‐HPA‐15b is responsible for the refractory state in this patient.Conclusion: In this study, we found alloimmunization against HPA‐15a and ‐15b in Japanese populations and demonstrated the relevance of these antibodies in a patient with PTR.
- 20 March 2013
- Published by Wiley in Tissue Antigens
- Vol. 81 (4) , 227-228
The frequencies of SLC44A2 alleles among the Japanese population
- 20 March 2013
- Published by Wiley in Tissue Antigens
- Vol. 81 (4) , 227-228
The frequencies of SLC44A2 alleles among the Japanese population
- 9 July 2012
- Published by Wiley in Tissue Antigens
- Vol. 80 (4) , 336-340
The frequencies of human neutrophil alloantigens among the Japanese population
Human neutrophil antigens (HNAs) play an important role in a variety of clinical conditions including immune‐mediated neutropenia, non‐hemolytic transfusion reactions, and transfusion‐related acute lung injury. The aim of this study was to investigate the frequency distribution of HNAs‐1 to ‐5 among the Japanese population. We analyzed samples from 570 healthy Japanese by molecular and serologic techniques to estimate the gene frequencies of HNAs‐1 to ‐5. DNA samples were obtained and typed for the HNA‐1 (n = 523), ‐3 (n = 570), ‐4 (n = 570), and ‐5 (n = 508), by molecular techniques. The HNA‐1 genotype was determined by using a commercial polymerase chain reaction‐reverse sequence‐specific oligonucleotide probes (PCR‐rSSOP) kit. The HNA‐3 to ‐5 genotypes were determined by the PCR‐sequence specific primer (PCR‐SSP), previously described, with a small modification. The HNA‐2a phenotype was determined in 301 donors by granulocyte immunofluorescence test. In Japanese, the gene frequencies of HNA‐1a, ‐1b, and ‐1c were 0.623, 0.377, and 0.000, respectively. The frequency of HNA‐2a phenotype was 0.987, and the gene frequencies of HNA‐3a and ‐3b were 0.654 and 0.346, respectively. HNA‐4a and ‐4b were found at 1.000 and 0.000, respectively, and HNA‐5a and ‐5b at 0.840 and 0.160, respectively. We describe, for the first time, the frequencies of all HNAs (HNA‐1 to ‐5) among the Japanese population. This study will be helpful for the prediction of the risk of alloimmunization to HNA, especially to determine the risk of HNA alloantibody production by transfusion of HNA incompatible blood and feto‐maternal incompatibility.
- 9 July 2012
- Published by Wiley in Tissue Antigens
- Vol. 80 (4) , 336-340
The frequencies of human neutrophil alloantigens among the Japanese population
Human neutrophil antigens (HNAs) play an important role in a variety of clinical conditions including immune‐mediated neutropenia, non‐hemolytic transfusion reactions, and transfusion‐related acute lung injury. The aim of this study was to investigate the frequency distribution of HNAs‐1 to ‐5 among the Japanese population. We analyzed samples from 570 healthy Japanese by molecular and serologic techniques to estimate the gene frequencies of HNAs‐1 to ‐5. DNA samples were obtained and typed for the HNA‐1 (n = 523), ‐3 (n = 570), ‐4 (n = 570), and ‐5 (n = 508), by molecular techniques. The HNA‐1 genotype was determined by using a commercial polymerase chain reaction‐reverse sequence‐specific oligonucleotide probes (PCR‐rSSOP) kit. The HNA‐3 to ‐5 genotypes were determined by the PCR‐sequence specific primer (PCR‐SSP), previously described, with a small modification. The HNA‐2a phenotype was determined in 301 donors by granulocyte immunofluorescence test. In Japanese, the gene frequencies of HNA‐1a, ‐1b, and ‐1c were 0.623, 0.377, and 0.000, respectively. The frequency of HNA‐2a phenotype was 0.987, and the gene frequencies of HNA‐3a and ‐3b were 0.654 and 0.346, respectively. HNA‐4a and ‐4b were found at 1.000 and 0.000, respectively, and HNA‐5a and ‐5b at 0.840 and 0.160, respectively. We describe, for the first time, the frequencies of all HNAs (HNA‐1 to ‐5) among the Japanese population. This study will be helpful for the prediction of the risk of alloimmunization to HNA, especially to determine the risk of HNA alloantibody production by transfusion of HNA incompatible blood and feto‐maternal incompatibility.
- 1 March 2012
- Vol. 32 (3) , 865-72
SN-38 overcomes chemoresistance of colorectal cancer cells induced by hypoxia, through HIF1alpha.
Cancer cells can acquire resistance to therapy under hypoxic condition. We aimed to investigate the mechanisms regulating chemoresistance induced by hypoxia. Human colorectal cancer cells, HT-29 and SW480, were cultured under hypoxic conditions and the sensitivity to 5-fluorouracil (FU), oxaliplatin, and SN-38 (active metabolite of irinotecan) was tested. The cell cycle was evaluated by flow cytometry after staining of cells with propidium iodide (PI). hypoxia-inducible factor 1α (HIF-1α) expression was evaluated by western blot analysis. Hypoxia induced strong G(0)/G(1) cell cycle arrest of cancer cells and abrogated the cytotoxic effects of 5-FU and oxaliplatin, but not that of SN-38. This effect was dependent on the significant inhibition of the accumulation of HIF-1α in cancer cells cultured under hypoxia by SN-38. Neither 5-FU nor oxaliplatin affected HIF-1α expression. SN-38, through inhibition of HIF-1α can overcome chemoresistance under hypoxic conditions of colon cancer cells.
- 1 March 2012
- Vol. 32 (3) , 865-72
SN-38 overcomes chemoresistance of colorectal cancer cells induced by hypoxia, through HIF1alpha.
Cancer cells can acquire resistance to therapy under hypoxic condition. We aimed to investigate the mechanisms regulating chemoresistance induced by hypoxia. Human colorectal cancer cells, HT-29 and SW480, were cultured under hypoxic conditions and the sensitivity to 5-fluorouracil (FU), oxaliplatin, and SN-38 (active metabolite of irinotecan) was tested. The cell cycle was evaluated by flow cytometry after staining of cells with propidium iodide (PI). hypoxia-inducible factor 1α (HIF-1α) expression was evaluated by western blot analysis. Hypoxia induced strong G(0)/G(1) cell cycle arrest of cancer cells and abrogated the cytotoxic effects of 5-FU and oxaliplatin, but not that of SN-38. This effect was dependent on the significant inhibition of the accumulation of HIF-1α in cancer cells cultured under hypoxia by SN-38. Neither 5-FU nor oxaliplatin affected HIF-1α expression. SN-38, through inhibition of HIF-1α can overcome chemoresistance under hypoxic conditions of colon cancer cells.
- Open Access
- 15 July 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 370
Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells
Chloroquine (CQ), the worldwide used anti-malarial drug, has recently being focused as a potential anti-cancer agent as well as a chemosensitizer when used in combination with anti-cancer drugs. It has been shown to inhibit cell growth and/or to induce cell death in various types of cancer. 5-Fluorouracil (5-FU) is the chemotherapeutic agent of first choice in colorectal cancer, but in most cases, resistance to 5-FU develops through various mechanisms. Here, we focused on the combination of CQ as a mechanism to potentiate the inhibitory effect of 5-FU on human colon cancer cells. HT-29 cells were treated with CQ and/or 5-FU, and their proliferative ability, apoptosis and autophagy induction effects, and the affection of the cell cycle were evaluated. The proliferative ability of HT-29 was analyzed by the MTS assay. Apoptosis was quantified by flow-cytometry after double-staining of the cells with AnnexinV/PI. The cell cycle was evaluated by flow-cytometry after staining of cells with PI. Autophagy was quantified by flow-cytometry and Western blot analysis. Finally, to evaluate the fate of the cells treated with CQ and/or 5-FU, the colony formation assay was performed. 5-FU inhibited the proliferative activity of HT-29 cells, which was mostly dependent on the arrest of the cells to the G0/G1-phase but also partially on apoptosis induction, and the effect was potentiated by CQ pre-treatment. The potentiation of the inhibitory effect of 5-FU by CQ was dependent on the increase of p21Cip1 and p27Kip1 and the decrease of CDK2. Since CQ is reported to inhibit autophagy, the catabolic process necessary for cell survival under conditions of cell starvation or stress, which is induced by cancer cells as a protective mechanism against chemotherapeutic agents, we also analyzed the induction of autophagy in HT-29. HT-29 induced autophagy in response to 5-FU, and CQ inhibited this induction, a possible mechanism of the potentiation of the anti-cancer effect of 5-FU. Our findings suggest that the combination therapy with CQ should be a novel therapeutic modality to improve efficacy of 5-FU-based chemotherapy, possibly by inhibiting autophagy-dependent resistance to chemotherapy.
- 15 July 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 370
Open AccessChloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells
Chloroquine (CQ), the worldwide used anti-malarial drug, has recently being focused as a potential anti-cancer agent as well as a chemosensitizer when used in combination with anti-cancer drugs. It has been shown to inhibit cell growth and/or to induce cell death in various types of cancer. 5-Fluorouracil (5-FU) is the chemotherapeutic agent of first choice in colorectal cancer, but in most cases, resistance to 5-FU develops through various mechanisms. Here, we focused on the combination of CQ as a mechanism to potentiate the inhibitory effect of 5-FU on human colon cancer cells. HT-29 cells were treated with CQ and/or 5-FU, and their proliferative ability, apoptosis and autophagy induction effects, and the affection of the cell cycle were evaluated. The proliferative ability of HT-29 was analyzed by the MTS assay. Apoptosis was quantified by flow-cytometry after double-staining of the cells with AnnexinV/PI. The cell cycle was evaluated by flow-cytometry after staining of cells with PI. Autophagy was quantified by flow-cytometry and Western blot analysis. Finally, to evaluate the fate of the cells treated with CQ and/or 5-FU, the colony formation assay was performed. 5-FU inhibited the proliferative activity of HT-29 cells, which was mostly dependent on the arrest of the cells to the G0/G1-phase but also partially on apoptosis induction, and the effect was potentiated by CQ pre-treatment. The potentiation of the inhibitory effect of 5-FU by CQ was dependent on the increase of p21Cip1 and p27Kip1 and the decrease of CDK2. Since CQ is reported to inhibit autophagy, the catabolic process necessary for cell survival under conditions of cell starvation or stress, which is induced by cancer cells as a protective mechanism against chemotherapeutic agents, we also analyzed the induction of autophagy in HT-29. HT-29 induced autophagy in response to 5-FU, and CQ inhibited this induction, a possible mechanism of the potentiation of the anti-cancer effect of 5-FU. Our findings suggest that the combination therapy with CQ should be a novel therapeutic modality to improve efficacy of 5-FU-based chemotherapy, possibly by inhibiting autophagy-dependent resistance to chemotherapy.